Treatments & Services

Brentuximab Vedotin in combination with Nivolumab for Hodgkins Lymphoma

A phase 2 open-label study of Brentuximab Vedotin in combination with Nivolumab in front-line therapy of Hodgkin Lymphoma (HL) in adults age 60 and above

Disease Types: Lymphoma

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A phase 2 open-label study of Brentuximab Vedotin in combination with Nivolumab in front-line therapy of Hodgkin Lymphoma (HL) in adults age 60 and above